Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 67 of 242 for:    furosemide

Prevention of Severe Postpartum Hypertension

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02450773
Recruitment Status : Recruiting
First Posted : May 21, 2015
Last Update Posted : October 3, 2019
Sponsor:
Information provided by (Responsible Party):
Method Tuuli, Indiana University

Brief Summary:
The purpose of this study is to determine whether postpartum administration of furosemide to women with antepartum hypertensive disorders (gestational hypertension, preeclampsia) or elevated blood pressure in the first 24 hours following delivery reduces severe postpartum hypertension.

Condition or disease Intervention/treatment Phase
Hypertension Drug: Furosemide Drug: Potassium chloride Drug: Placebo #1 Drug: Placebo #2 Phase 2

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 248 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Prevention
Official Title: Furosemide for Prevention of Severe Postpartum Hypertension: a Randomized Controlled Trial
Study Start Date : August 2015
Estimated Primary Completion Date : May 2022
Estimated Study Completion Date : May 2022

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Experimental: Furosemide/Potassium chloride
40 mg furosemide; 20 meq potassium chloride
Drug: Furosemide
40 mg furosemide on postpartum day 1-6
Other Name: Lasix

Drug: Potassium chloride
20 meq potassium chloride on postpartum day 1-6
Other Name: KCl

Placebo Comparator: Placebo
Placebo #1, Placebo #2
Drug: Placebo #1
Placebo (for furosemide)

Drug: Placebo #2
Placebo (for KCl)




Primary Outcome Measures :
  1. Composite maternal morbidity [ Time Frame: 0-6 weeks following delivery ]
    Requiring antihypertensive medication at discharge, readmission for blood pressure, end-organ damage from hypertension


Secondary Outcome Measures :
  1. Adverse events associated with furosemide [ Time Frame: 0-6 weeks following delivery ]
    Hypokalemia

  2. Adverse events associated with furosemide [ Time Frame: 0-6 weeks following delivery ]
    hyperglycemia

  3. Adverse events associated with furosemide [ Time Frame: 0-6 weeks following delivery ]
    oliguria

  4. Adverse events associated with furosemide [ Time Frame: 0-6 weeks following delivery ]
    hypotension

  5. Adverse events associated with furosemide [ Time Frame: 0-6 weeks following delivery ]
    elevated serum creatinine


Other Outcome Measures:
  1. Cardiovascular changes following delivery [ Time Frame: 0-1 week following delivery ]
    Maternal echocardiogram, renin, aldosterone, B-natriuretic peptide levels



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   Child, Adult, Older Adult
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

Women > 18 years of age or emancipated minors

Women undergoing vaginal or cesarean delivery at > 23 weeks gestation with:

  • Antepartum diagnosis of gestational hypertension
  • Antepartum diagnosis of preeclampsia
  • Antepartum diagnosis of preeclampsia with severe features
  • Mild hypertension (<150/100) in first 24 hours following delivery

Exclusion Criteria:

  • Chronic hypertension
  • Allergy to furosemide
  • Pre-existing hypokalemia (serum K < 3.0 meq/L)
  • Chronic kidney disease
  • Serum Cr > 1.1
  • Inability to obtain informed consent
  • Pre-existing diuretic use
  • Oliguria

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02450773


Contacts
Layout table for location contacts
Contact: Maureen Mullen, BSN 317-948-7587 maamulle@iu.edu

Locations
Layout table for location information
United States, Indiana
Indiana University School of Medicine Recruiting
Indianapolis, Indiana, United States
Contact: Maureen Mullen, BSN    317-948-7587    maamulle@iu.edu   
Contact: Shannon Barnes, MSN    317-948-7624    shanbarn@iupui.edu   
Principal Investigator: Methodius G Tuuli, MD, MPH         
United States, Missouri
Washington University School of Medicine Completed
Saint Louis, Missouri, United States, 63110
Sponsors and Collaborators
Indiana University
Investigators
Layout table for investigator information
Principal Investigator: Methodius G Tuuli, MD, MPH Indiana University School of Medicine

Layout table for additonal information
Responsible Party: Method Tuuli, Professor of Obstetrics and Gynecology, Indiana University
ClinicalTrials.gov Identifier: NCT02450773     History of Changes
Other Study ID Numbers: 201501157
First Posted: May 21, 2015    Key Record Dates
Last Update Posted: October 3, 2019
Last Verified: October 2019
Keywords provided by Method Tuuli, Indiana University:
postpartum
preeclampsia
gestational hypertension
Additional relevant MeSH terms:
Layout table for MeSH terms
Hypertension
Vascular Diseases
Cardiovascular Diseases
Furosemide
Diuretics
Natriuretic Agents
Physiological Effects of Drugs
Sodium Potassium Chloride Symporter Inhibitors
Membrane Transport Modulators
Molecular Mechanisms of Pharmacological Action